HEMASORB is a ready-to-use, biocompatible, water resistant and absorbable putty designed to rapidly stop bleeding when applied to damaged or cut bone.
ORTHOCON president and CEO John Pacifico said they are confident that HEMASORB will provide surgeons in Europe and Canada a tool to assist in their management of intra-operative bone bleeding, and they fully expect HEMASORB to become the standard of care for bone hemostasis.
HEMASORB previously has cleared the US Food and Drug Administration (FDA) 510(k) premarket approval and was first introduced in the US in 2010.
ORTHOCON will continue to focus its efforts on increasing adoption of HEMASORB in the US and is actively pursuing product distribution partnerships in Europe and Canada to ensure HEMASORB becomes widely available to surgical patients in these markets.
